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eligible persons aged 2-59 years of age. The study objectives were to determine the
cost-effectiveness of LAIV compared to TIV in Canadian children and adolescents
from aMinistry of Health (MoH) perspective and a societal perspective.METHODS:
A previously published US cost-effectiveness model using patient-level data to
compare LAIV and TIV was supplemented by secondary (e.g. literature) and pri-
mary data (i.e. survey of 144 Canadian physicians). To compare the costs and ben-
efits of LAIV and TIV, a cost-utility analysis was conducted. Parameter uncertainty
was addressed through probability sensitivity analysis (PSA). RESULTS: Although
LAIV increased vaccination costs compared to TIV, LAIV reduced the number of
influenza illness cases and lowered the number of hospitalizations, ER visits, out-
patient visits andparents’ days lost fromwork. The estimated offsets in direct costs
savedwere $4.19 per vaccinated child aged 2-17 years. Societal savings were $35.33
per vaccinated child. When costs and outcomes were considered, LAIV was the
dominant strategy when compared to TIV. At a willingness to pay of $50,000 per
QALY gained, the results of the PSA indicated that the probability of LAIV being
cost-effective was almost 1. CONCLUSIONS: LAIV reduces the burden of influenza
in children and adolescents. Consistent with US results, vaccinating children with
LAIV instead of TIV is the dominant strategy from a societal and MoH perspective.
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OBJECTIVES: To estimate the long-term costs and effectiveness of entecavir com-
pared with lamivudine and adefovir in treating chronic HBeAg-positive infection.
METHODS:We compare key outcomes related to survival, costs, and QOL for HBV
patients. A lifetime Markov model was used to estimate the expected outcomes
and costs for HBV patients treated with entecavir vs lamivudine and adefovir. The
impact of treatingHBVwith entecavir, lamivudine and adefovir in patientswho are
positive for hepatitis B e antigen (HBeAg) was based on the efficacy and safety
results of the Phase 3, double-blind, randomized controlled trial. Utility values
were derived from published literature. The cost-effective analysis was conducted
from the Mexican Healthcare perspective. Costs were derived from the literature
and expert interviews, future costs and effects were discounted at 5% per recom-
mendations for analyses in Mexico. All costs are presented in 2010 US dollars.
Multiple 1-way sensitivity analyses were performed to address uncertainty.
RESULTS: The model projects an accumulated discounted cost to the Mexican
healthcare systemper patient receiving the entecavir regimen of $28,356 compared
to $28,325 for adefovir and $27,901 for lamivudine regimen. The base-case analysis
presented incremental cost-effectiveness ratios for entecavir vs adefovir and lami-
vudine of $123 per QALY and $ 1,574 per QALY respectively. These values are in
accordance with the recommendations of the Commission on Macroeconomics
and Health, WHO, suggesting that health technologies with ICERs below the per
capita GDP are considered very cost-effective. Results were robust to various as-
sumptions tested in the sensitivity analysis. CONCLUSIONS: Results from this
study analyses suggest that in the Mexican setting, use of entecavir in place of
adefovir and lamivudine for treatment of HBV is likely to be cost effective. These
conclusions are supported by conservative assumptions and sensitivity analysis.
Infection – Patient-Reported Outcomes & Preference-Based Studies
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OBJECTIVES: Community pharmacies focused on HIV offer enhanced services to
assist patients taking antiretrovirals (ARV), yet the impact of these services is un-
clear. The objective of this study was to determine differences in patient charac-
teristics, regimen characteristics, and regimen refill adherence for HIV-SP versus
NSP users. METHODS: We conducted a retrospective database study of patients
with ARV claims fromMay 2007 – August 2009 at CaliforniaWalgreens pharmacies.
A modified medication possession ratio (mMPR) was used to calculate regimen
refill adherence. Patients were deemed “regimen adherent” on any given study day
if they possessed three or more antiretroviral drugs that included: a protease in-
hibitor, a non-nucleoside reverse transcriptase inhibitor, raltegravir, an entry in-
hibitor, abacavir, or tenofovir. A patient’s regimen adherent days were summed,
then divided by the total number of study days contributed to calculate themMPR.
A multivariable logistic regression model was constructed to determine indepen-
dent factors which contributed to having  95% regimen refill adherence.
RESULTS: 4254 HIV-SP and 11679NSP userswere included. Compared to NSP users,
HIV-SP users traveled farther to their pharmacies (5.03 vs. 1.26 miles), filled more
chronic disease medications (35% vs. 30%) and psychotropics (42% vs. 39%), and
received more fixed dose combination (FDC) ARVs (92% vs. 83%;); all p  0.01.
Median regimenmMPRwas higher for HIV-SP users (90% vs. 77%, p 0.0001). After
adjustment for various factors, both the use of HIV-SP (OR 1.79, 95% CI 1.72-2.08)
and fixed dose combination ARV tablets (OR3.3, 95% CI 2.86-4.01) were associated
with a greater likelihood of having95% regimen refill adherence. CONCLUSIONS:
Patients filling their prescriptions at HIV-SP are more likely to use fixed dose com-
bination ARV and have higher regimen refill adherence; particularly those taking
FDCs. HIV-SP should be further explored to determine whether specific services
improve patient adherence.
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OBJECTIVES: Immunization dosewas considered as amissed immunization dose if
pediatric didn’t receive at least one immunization dose. The aims of this study are
to determine the frequency and percent of missed doses among pediatric immu-
nization schedule, to determine the number of immunization doses missed by
each child, and to evaluate the correlation between missed dose frequency and
parent’s knowledge.METHODS: Data was collected retrospectively from 528 pedi-
atric immunization cards in Iraq to obtain the immunization history of each indi-
vidual child. This study was restricted the analyses to the vaccines administered
before age of 2 years. Each pediatric must received seven doses at seven different
times, every dose consist of many types of vaccines. Validated questionnaire was
used to measure immunization parent’s knowledge and Spearman rho correlation
test was used to evaluate the correlation between missed dose frequency and
parent’s knowledge. RESULTS:More than 30% ofmissed immunization doses were
shown in the seventh or last dose (OPVDTP) at 18 months of age. The majority of
pediatrics (54.1%) was immunized without any missed immunization dose out of
seven immunization doses. Four pediatrics (0.8%) were only having six missed
immunization doses. Missed immunization dose found to be negatively correlated
with knowledge score (correlation 0.263, P-value0.001). CONCLUSIONS: This
study suggests that compliancewithWHO immunization recommendations is low
and inappropriate immunization doses were occurred frequently, and leading to
incomplete or partial immunization compliance. With an increase in parent’s
knowledge of immunization guidelines against infectious agents, it is very impor-
tant to implement strategies that will lead to improved and developed immuniza-
tion practice and childhood immunization coverage in the future.
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OBJECTIVES: Immunization dosewas considered as a right immunization dose if it
was administered at the recommended age. The aims of this study are to deter-
mine the frequency and percent of this type of doses among pediatric immuniza-
tion schedule, to determine the number of right immunization dose received by
each child, and to evaluate the correlation between right dose frequency and par-
ent’s knowledge.METHODS: Data was collected retrospectively from 528 pediatric
immunization cards in Iraq to obtain the immunization history of each individual
child. This study was restricted the analyses to the vaccines administered before
age 2 years. Each pediatric must received seven doses at seven times, every dose
consist of many types of vaccines. Validated questionnaire was used to measure
immunization parent’s knowledge and Spearman rho correlation test was used to
evaluate the correlation between right doses frequency and parent’s knowledge.
RESULTS:More than 45% of right immunization doses were shown in the first dose
(BCGOPVHEP B.) at first week of pediatric life. The majority of pediatric (28%)
were immunized with one right immunization dose out of seven immunization
doses. Four pediatric (0.8%) were only immunized with seven normal immuniza-
tion doses, while 132 pediatric (25%) were immunized without any dose as right
immunization dose. Right immunization dose found to be positively correlated
with knowledge score (correlation 0.358, P-value0.001). CONCLUSIONS: This
study found that compliance with WHO immunization recommendations is low
and inappropriate immunization doses were occur frequently, and leading to in-
complete or partial immunization compliance.With an increase in parent’s knowl-
edge of immunization guidelines against infectious agents, it is very important to
implement strategies that will lead to improved and developed immunization
practice and childhood immunization coverage in the future.
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OBJECTIVES: Vaccine barriers addressed in this study were included lack of edu-
cation, lack of funding, lack of vaccine availability, lack of medical facilities, and
fear of a side effect. The aims of this study are to determine immunization barriers
and to evaluate the solutions suggested by parents. METHODS: A cross sectional
prospective surveywas carried out among 528 Iraqis parentswith child had improper
immunization schedule to obtaineddemographic data of immunized children. Trans-
lated and validated questionnaire were administered to parents, it consisted of mul-
tiple choice questions. The questions were related to the immunization barriers and
how to decrease this barrier? RESULTS:More than 90% of pediatrics have improper
immunization schedule with immunization doses errors. The majority of parents
perceived that the lack of vaccine availabilitywas themost common immunization
barrier (51.5%), and more than 42% of parents perceived that the lack of education
was the important barrier, while 88.4% of parents were thought that the lack of
founding wasn’t important immunization barrier. More than 60% of parents sug-
gested increasing immunization programs in the media to promote pediatrics im-
munization, and 44.7% of parents suggested increasing mother’s education to pro-
mote immunization. But 77.5% of parents thought that any increase in fundingwill
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